INNATE PHARMA SA-SPONS ADR (IPHA) Stock News

USA - NASDAQ:IPHA - US45781K2042 - ADR

1.91 USD

-0.03 (-1.55%)

Last: 9/19/2025, 10:28:39 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IPHA Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Benzinga - Mentions: AVAV TSEM PGR RMD

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

a day ago - By: Benzinga - Mentions: CBRL CSX PGR CYRX ...

Alphabet To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday

2 days ago - By: Innate Pharma SA

Innate Pharma Reports First Half 2025 Business Update and Financial Results

4 days ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

9 days ago - By: Innate Pharma SA

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

17 days ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

2 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025

2 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

3 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

3 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

3 months ago - By: Innate Pharma SA

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

4 months ago - By: Innate Pharma SA

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

4 months ago - By: Innate Pharma SA

Outcome of Innate Pharma’s 2025 Annual General Meeting

4 months ago - By: Innate Pharma SA

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

4 months ago - By: Innate Pharma SA

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

4 months ago - By: Innate Pharma SA

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

4 months ago - By: Innate Pharma SA

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

4 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

5 months ago - By: Innate Pharma SA

Innate Pharma announces conference call and webcast for Q1 2025 business update

5 months ago - By: Innate Pharma SA

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

5 months ago - By: Innate Pharma SA

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

5 months ago - By: Innate Pharma SA

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

5 months ago - By: Innate Pharma SA

Innate Pharma Announces €15M Investment by Sanofi

5 months ago - By: Innate Pharma SA

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

5 months ago - By: Innate Pharma SA

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

5 months ago - By: Innate Pharma SA

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

6 months ago - By: Innate Pharma SA

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

6 months ago - By: Innate Pharma SA

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

6 months ago - By: Innate Pharma SA

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

6 months ago - By: Innate Pharma SA

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

6 months ago - By: Innate Pharma SA

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

7 months ago - By: Innate Pharma SA

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

7 months ago - By: Innate Pharma SA

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome